Interestingly, pharmacological inhibition of β-catenin binding to the promoter regions of both Fra-2 and ARID5A, reverts the phenotype switch of TAM2 to TAM1, eventually decreasing NSCLC growth and metastasis [111]. The gene discussed is ARID5A; the disease is non-small cell lung carcinoma.